AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- Metformin significantly increases the frequency of ovulation and decreases circulating testosterone in women with polycystic ovary syndrome who are not obese and have normal indices of insulin sensitivity, Dr. Jean-Patrice Baillargeon said at the annual meeting of the Endocrine Society.
Previous studies have shown only that insulin-sensitizing drugs are useful in polycystic ovary syndrome (PCOS) patients generally; many of these patients are insulin resistant and/or overweight, said Dr. Baillargeon of the Medical College of Virginia, Richmond.
Moreover, the current study found that metformin treatment significantly reduced insulin levels, even though the study patients were not apparently insulin resistant. This finding suggests some insulin resistance in all women with PCOS, Dr. Baillargeon said.
In the study 100 women with PCOS who were not obese and had normal indices of insulin sensitivity were randomized to receive 6 months of treatment with either metformin, rosiglitazone, metformin plus rosiglitazone, or placebo.
The mean number of ovuladons over the 6 months--defined as a serum progesterone level above 4.0 ng/mL followed by menstrual bleeding--was 0.4 for the patients assigned to placebo, 3.3 for those on metformin, 2.4 for those on ...